The purpose of this study is to quantify and publish participants' relative preferences for outcomes of chemotherapy and novel oral hormonal agents when added to androgen deprivation therapy (ADT) for participants with locally-advanced and metastatic hormone-sensitive prostate cancer (mHSPC). This study will also quantify the importance of administration factors related to convenience relative to treatment outcomes.

The study will develop and administer a discrete-choice experiment (DCE) to quantify tradeoff preferences of participants with mHSPC and locally-advanced prostate cancer in various countries. Data/surveys are being collected in: United States, Canada, UK, France, Spain, Japan, China and South Korea.

Inclusion Criteria:

For interviews (attribute prioritization and pretest interviews)

• Diagnosis of mHSPC with or without previous experience with ADT
• Able to read and understand the survey language
• Able to provide informed consent For online survey
• Diagnosis of mHSPC or locally-advanced prostate cancer with or without previous experience with ADT
• Able to read and understand the survey language
• Able to provide informed consent

Exclusion Criteria:

Not applicable

Participants with mHSPC or locally-advanced prostate cancer with or without previous experience with ADT.

Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.